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ABSTRACT 
 
Background 
Guidelines suggest treatment in rheumatoid arthritis(RA) to target remission, in close consultation 
with the patient. Our recent qualitative study of the patients’ perspective on remission in RA 
identified 26 domains. The current study aimed to identify a short list of the most important aspects 
to inform future research.  
 
Methods 
RA patients from the Netherlands, the United Kingdom, Austria, Denmark, France, and the United 
States completed a survey that contained all domains identified in our qualitative study. They rated 
domains for importance (‘not important’, ‘important’, or ‘essential’ to characterise a period of 
remission) and if important or essential, whether this domain needs to be 'less', 'almost gone', or 
'gone' to reflect remission. Respondents were also asked to determine their personal top three most 
important/essential domains. Frequency of specific domains in the top three was calculated and 
domains were sorted on the percentage of patients that evaluated a particular domain as ‘essential’. 
 
Results 
Of 274 respondents, 75% were female, mean(SD) age 57(13) years, disease duration 12(9) years. 
The top 3 were: pain (67%), fatigue (33%) and independence (19%); domains most frequently 
rated as ‘essential’ were: pain (60%), being mobile (52%), physical function (51%), being 
independent (47%) and fatigue (41%). Pain needed to be less (13%), almost gone (42%) or gone 
(45%) to reflect remission. Similar patterns were seen for fatigue, independence, mobility and 
physical functioning. 
 
Conclusions 
Patients identified pain, fatigue and independence as the most important domains of RA disease 
activity that need to be improved in order to reflect remission. 
 
Word count: 250 
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Patients with rheumatoid arthritis (RA) are at risk of severe bone and cartilage damage in affected 
joints, causing chronic pain, fatigue and other extra-articular manifestations with a significant 
impact on daily life. The degree of disease activity and response to treatment are traditionally 
determined by evaluation of the RA core set or indices derived thereof.(1-2) The core set contains the 
patient reported outcomes (PROs) physical function, pain and global assessment of disease activity. 
Although not consistently associated with joint damage and differential response in disease stages, 
these PROs have been found to be at least as relevant as more ‘objective’ physical and biochemical 
measures in assessing baseline disease status, improvement during interventions or prediction of 
long-term outcome.(3-4) Moreover, the relevance of some of them, especially those evaluating 
physical function, is revealed by observations that increasing joint damage causes increasing 
irreversibility of functional impairment, even if clinical activity has subsided into remission.(5,6) 
It is becoming increasingly clear both in and outside rheumatology that patients are crucial partners 
in obtaining relevant information, adding unique skills, values and experiences to research.(7) 
Patients have identified domains such as fatigue and sleep quality to be important and thus core 
areas for measurement. Subsequent research has shown measurement of fatigue, one of the most 
important problems identified by RA patients, to be highly reliable, sensitive to change and an 
independent determinant of disease activity.(8-10) As a consequence, the scientific community now 
recognizes fatigue as a core PRO to be measured in all RA clinical trials.(11,12) Other products of close 
cooperation between patients and professionals include the recent development of patient-derived 
scores to capture the impact of RA and psoriatic arthritis (PsA) on daily life.(13,14) 
In the last decade, the development of new drugs for the treatment of RA has made a state of 
minimal disease activity and even remission an attainable goal in most patients.(15-18) Because 
treatments are increasingly targeted at achieving remission, a good definition of remission is vital. 
In 2011, the three leading international rheumatology organisations, i.e. the American College of 
Rheumatology (ACR), the European League Against Rheumatism (EULAR) and the Outcome 
Measures in Rheumatology group (OMERACT), led the initiative which redefined remission in RA.(19-
21) To this end, all important prognostic factors and outcome measures available in clinical trial data 
were evaluated for their potential use in defining remission. However, this included only the three 
core set PROs patient global, pain and physical function, as data on other potential important 
aspects of remission from the patient perspective were not available.  
In response, both patients and professionals identified the need to study the concept of remission 
from a patient perspective, to evaluate whether additional domains (and PROs) could optimize 
targeted therapy(22). Therefore, we recently undertook a qualitative study to understand the patient 
perspective on remission in RA.(23) Three major themes of patient perceived remission emerged:  
1) symptoms such as pain, stiffness and fatigue would either be absent or be reduced in intensity,  
2) the impact of the disease on daily life would diminish as shown by increased independence, the 
ability to do valued activities, improved mood and the ability to cope; 3) remission would lead to a 
return to normality, including the ability to work, enjoy one’s family role and be seen as normal by 
other people. Patients felt the concept of remission was influenced by ageing, side effects of 
medication, comorbidities, accrued damage to joints and disease duration. This qualitative research 
identified many domains of interest to patients, but did not indicate the importance of one domain 
over another.  
The aim of the current descriptive study was to determine the importance of specific symptoms, 
aspects of disease impact and normality in defining remission in RA from the patient perspective 
through a survey, to complete the information necessary for optimal clinical management. 
 
METHODS 
Patients: Patients >18 years of age with a confirmed diagnosis of RA (2010 criteria)(24) receiving 
usual care in one of 5 centers (VU University Medical Center/Reade in Amsterdam, the Netherlands; 
Medical University of Vienna, Austria; Bristol Royal Infirmary in Bristol, United Kingdom (UK); Center 
for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark;  Université Pierre et 
Marie Curie and Hopital Pitie-Salpetriere Paris in Paris) were invited to participate in this study. 
Medical ethical committees in these centers approved the study protocol where applicable and 
patients gave their informed consent before participation. In addition, a fixed sample of 50 RA 
patients were recruited through a known community (MediGuard.org) with pre-existing consent to 
contact for research purposes in the United States of America (US).(25)  
Eligible patients had to speak, read and write the local language sufficiently to understand the study 
and complete the survey (physician’s judgement where applicable). 
In addition, all patient representatives who attended OMERACT 12 in 2014 were invited to 
participate by email(26) , as well as all the patients who participated in one of the 9 focus group 
discussions prior to this study.(23) 
   4 
 
Data collection process: In Bristol, Amsterdam, Vienna and Copenhagen, the surveys and reply-
envelopes were distributed in the clinic; in Paris and the US they were distributed by email.  
As the word ‘remission’ is a common word in the English language and might imply certain 
presumptions, this term was not used during the recruitment and data collection phase. Instead 
remission was formulated as ‘disease activity as good as gone’. Where available in routine practice, 
a recent 28-joint count, physician global assessment and acute phase reactant were collected from 
the hospital files, within a period of 3 months before or after completion of the survey.  
 
The survey: The goal of the survey was to determine a short list of the most important items that 
reflect remission according to patients with RA. The survey (online appendix I) contained all 26 
domains of remission that were identified in previous focus group discussions in Bristol, Vienna and 
Amsterdam(23), formulated as items which patients were asked to rate for importance. In addition, 
patients were asked to add any missing aspects of remission in free text fields. During the 
qualitative study patients had indicated that demographic and disease specific aspects were 
important to interpret the data, and so information on age, gender, disease duration, co-morbidities 
and accrued joint damage was collected, all in a self-reported manner using the Routine Assessment 
of Patient Index Data 3 (RAPID3), with remission cut-off defined as 3 or less on a scale of 0 to 
30(27). Where possible, the Clinical Disease Activity Index (CDAI) was calculated, with remission cut-
off ≤2.8(28). 
German, French, Danish and Dutch versions of the survey were prepared by translation and back-
translation by the research team to verify the terminology. The language used was carefully written, 
based on the focus group terminology, and was reviewed by patient research partners (WH, MV and 
BD) to ensure that the instructions were clear to patients and that each item was understandable in 
terms of the RA symptoms and experience. 
To reduce any order effect on decision-making, two versions of the survey were distributed in the 
clinics (but not for the emailed assessments) with the domains and the items within them randomly 
ordered.  
  
 Analysis: Patient characteristics were summarised as mean (standard deviation (SD)) or median 
(interquartile range (IQR)) where applicable. Fulfilment of RAPID3 remission, ACR/EULAR remission 
and CDAI remission was compared with the patients’ self-reported judgment of remission (‘disease 
as good as gone’: no/yes) to determine concordance between the clinical definition of remission and 
the patient’s judgment of remission, quantified using the kappa measure for agreement (with 0.75 
as excellent, 0.40 to 0.75 as fair to good, and below 0.40 as poor); 2 by 2 tables and chi-square 
tests were used.  
In order to determine the importance of domains, first, frequency of a particular domain mentioned 
in the top 3 was calculated. Second, domains that >30% of patients identified as ‘not important’ 
were removed. The remaining domains were sorted on the percentage of patients that evaluated a 
particular domain as ‘essential’. 
In order to evaluate robustness of the results, data were stratified by the influential factors as 
identified by patients in the qualitative study, including self-reported age (above or below 50 years), 
gender (male/female), disease duration (more or less than 2 years), comorbidity (no/yes) and 
accrued joint damage (no/yes), to see if these factors influence the patient perspective on 
remission. In addition, data were stratified by country and location of filling out the survey (clinic 
visit or by email). Chi square tests were used to determine statistical significance (if p<0.05) where 
relevant. 
 
RESULTS 
A total of 274 patients completed the questionnaire: 54 from the Netherlands, 33 from the UK, 51 
from Austria, 43 from Denmark, 43 from France, and 50 from the US. Response rate in the 
Netherlands and France was 59% and 42% respectively. 
The population was typical for RA (Table 1), with 75% females, mean (SD) age of 57 (13) years, 
disease duration of 12 (9) years with 10% disease duration <2 years and self-reported erosive 
disease of 41%. Remission as reported by the patient was present in 38% and according to the 
RAPID3 in 30%. Concordance was reasonably good: of the patients in self-reported remission, 61% 
were in RAPID3 remission; of the patients in RAPID3 remission, 79% were in self-reported remission 
(observed agreement, 79%; kappa 0.54).  
In the subgroup of patients with available clinical data (n=119), 42% were both in self-reported  
and in RAPID3 remission, and 24% in ACR/EULAR remission. Here concordance was good only in 
one direction: of patients in ACR/EULAR remission 86% were in self-reported remission (observed 
agreement, 76%; kappa 0.48) and 97% were in RAPID3 remission (observed agreement, 81%; 
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kappa 0.59); but only 50% of patients in self-reported remission and 56% of patients in RAPID3 
remission were in ACR/EULAR remission (Table 2). Of the patients with available CDAI (n=47), 
CDAI remission was present in 21%. Of these, all patients were in RAPID3 remission, 80% was in 
self-perceived remission (observed agreement, 70%; kappa 0.35) and 70% in ACR/EULAR remission 
(observed agreement, 81%; kappa 0.48).   
 
 
Table 1: Patient characteristics by site, all self-reported 
 All 
patients 
(n=274) 
Bristol 
(n=33) 
Vienna 
(n=51) 
Amster-
dam 
(n=54) 
Paris 
(n=43) 
Copen-
hagen 
(n=43) 
US 
(n=50) 
Gender  
(% female) 
75 73 75 76 79 61 82 
Age in years 
(mean (SD)) 
57 (13) 62  (14) 54 (14) 60 (12) 53 (13) 56 (13) 56 (11) 
Disease duration in 
years (mean, (SD)) 
12 (9)   8  (8) 11 (9) 14 (12) 12 (8) 13 (9) 11 (7) 
Experience with 
remission (% yes) 
74         52 88 76 72 91 60 
Currently in remission 
(% yes) 
38 18 45 46 51 44 16 
Self-reported 
deformities (% yes) 
41 97 41 54 19 30 52 
Pain (VAS 1 to 10) 3.5 (2.7) 5 (2.3) 2.4    (2.6) 3.1     (2.7) 3.4   (2.4) 2.6    (2.5) 5.0    (2.7) 
PtGA (VAS 1 to 10) 3.6 (2.7) 4.9 (2.3) 3.2    (2.8) 3.1     (2.5) 3.2   (2.6) 2.3    (2.0) 4.9    (2.9) 
RAPID3 (0-30) 8.9    (6.4) 13.6(5.2) 6.4    (6.2) 8.3     (6.3) 8.0   (5.4) 6.2    (5.5) 12.6  (6.2) 
RAPID3 near 
remission (% yes) 
30 3 51 37 23 44 8 
Ability to distinguish 
pain due to 
inflammation vs 
damage (% yes) 
60 52 68 70 51 62 54 
 
 
Table 2: Concordance between two patient-derived remission definitions and the ACR/EULAR remission 
definition (count (percentage)) 
  Self-reported remission         ACR/EULAR remission 
 Yes No Total    
ACR/EULAR 
remission                                         
yes 25 (51) 4 (6) 29 (24)    
no 24 (49) 66 (94) 90 (76)    
 total 49 (100) 70 (100) 119 (100) Yes no Total 
RAPID 3  
remission                         
yes 63 (61) 17 (10) 80 (30) 28 (97) 21 (24) 49 (42) 
No 40 (39) 151 (90) 191 (70) 1 (3) 67 (76) 68 (58) 
 total 103(100) 168 (100) 271 (100) 29 (100) 88 (100) 117 (100) 
 Yes 8     (40) 2        (7) 10 (21) 7     (54) 3      (9) 10    (21) 
CDAI* No 12   (60) 25     (93) 37 (79) 6     (46) 31   (91) 37    (79) 
 total 20 (100) 27   (100) 47(100) 13 (100) 34 (100) 47  (100) 
* no data shown for CDAI vs RAPID3, as overlap was 100% 
 
 
Patients that considered themselves in remission (n=103) had a mean patient global assessment of 
disease activity of 1.5 (1.5) and disease duration of 10 (7) years) in contrast to 4.8(2.5) and 13(10) 
years for those not in self-perceived remission (n=171). 
 
Most important domains 
The most often mentioned domains in the top 3 were: pain (67%), fatigue (33%) and independence 
(19%) (Table 3).  
Only one domain, ‘The way other people see me’, was regarded by more than 30% of patients 
(59%) as ‘not important’ and was removed from further analyses. The percentage of patients that 
choose a certain domain in their top 3 is shown in supplementary file II. Domains that were most 
frequently rated as ‘essential’ to characterise a period of remission were highly similar: pain (60%), 
being mobile (52%), physical function (51%), being independent (47%) and fatigue (41%) (Table 
4).  
   6 
 
Pain needed to be less (13%), almost gone (42%) or gone (45%) to reflect remission. Similar 
patterns were seen for fatigue (23%,40%,37%). Independence needed to be better (16%), almost 
normal (31%) or normal (53%), with similar patterns for mobility (16%,35%,49%) and physical 
functioning (14%,29%,57%). 
 
Stratifications 
Age: Importance of pain and fatigue were similar in patients under and over 50 years of age; 
however, independence was reported more frequently in the top 3 by patients over 50 (24%) as 
compared to patients under 50 years of age (12%) (p=0.03). 
Disease duration: Importance of pain and fatigue were similar in patients with early (≤2 years) vs 
long standing disease; numerically, independence was reported more frequently in the top 3 by 
patients with longstanding disease (21%) as compared to patients with early disease (12%) 
(p=0.40). 
Country: There were slight differences in the choice of a top 3 in the different countries (Table 3), 
although pain was the number one domain in all countries. Pain was mentioned in the top 3 by 65%, 
69%, 52%, 74%, 92% and 79% in the UK, Austria, Netherlands, France, US, and Denmark 
respectively (X2 p=0.001). Likewise, fatigue was among the top 3 (48%, 16%, 30%, 51%, 40%, 
29%, 35% (X2 p=0.005)) and to a lesser extent independence (39%, 20%, 27%, 21%, 6%, 17% 
and 21%(X2 p=0.01)). Bristol, Amsterdam and Paris had the same top 3 as that of the total group, 
but in Vienna, fatigue was replaced by stiffness and in both the US and Copenhagen, independence 
was replaced by swelling. 
Domains that were most frequently rated as ‘essential’ to characterize a period of remission were 
the same in the total group and in Bristol, while in Vienna fatigue was replaced by mental power, in 
Amsterdam fatigue was replaced by activities of daily living, in Paris fatigue was replaced by family 
role, in the US physical function was replaced by mobility and in Copenhagen fatigue and 
independence were replaced by work and activities of daily living. 
Version of the survey: The majority completed version 1 of the survey (79%). Patients that 
completed version 1 of the survey (appendix 1) reported pain in their top 3 more frequently (77%) 
compared to patients that completed version 2 of the survey (54%) (p=0.02). A similar pattern, 
although not significantly different, was seen for independence, reported by 19% in version 1 and 
29% in version 2. However, of the patients that completed version 2 of the survey, the most often 
mentioned domains in the top 3 were still pain (55%), fatigue (33%) and independence (29%). 
Other: There were no differences in choice of a top 3 between male and female patients; between 
patients that reported joints with vs without strongly reduced mobility, deformities, or joint 
replacement surgery; between patients that reported to have been diagnosed with other diseases; 
or between patients that completed the survey during their clinic visit, compared to patients that 
completed the survey electronically (at home). 
Table 4 gives an overview of the numerical differences of domains rated as essential for all 
stratifications. 
 
Table 3: Most important domains by site 
 Bristol Vienna Amsterdam Paris Copenhagen US 
Top 3 
1 Pain Pain Pain Pain Pain Pain 
2 Fatigue  Independence Fatigue Fatigue Fatigue Fatigue 
3 Independence Stiffness Independence Independence Swelling Swelling 
Domains rated as essential (%) 
1 Pain (67) Indep (53) Pain (57) Pain (72) Pain (51) Pain (70) 
2 Fatigue (66) Phys func (51) Phys func (46) Mobility (72) Phys func (49) Fatigue (60) 
3 Mobility (66) Pain (47) ADL (43) Phys func (67) Work (49) Indep (58) 
4 Indep (50) Mobility (43) Indep (41) Family (56) Mobility (46) Swelling (56) 
5 Phys func (50) Mental (43) Mobile (39) Indep (56) ADL (44) Mobility (54) 
Indep: independence; Phys func: physical functioning; ADL: activities of daily living 
 
 
DISCUSSION 
This survey study identified the three most important domains of patient perceived remission, based 
on preceding qualitative research on the patient perspective on remission in RA: the absence or 
reduction of pain and fatigue and the improvement or maintenance of independence.  
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Pain is the most predominant PRO assessed in rheumatic diseases, present in all core sets and 
frequently inquired after in clinical practice.(29)  Fatigue has been acknowledged as an essential PRO 
in recent years and is recommended to be reported in RA clinical trials;(11) however, independence is 
not a common PRO in rheumatology. We are not the first to report on independence as an important 
domain for patients with RA; a recent Czech study(30) reported a significant difference between the 
healthy population and RA patients in level of independence. In addition, qualitative work performed 
in Bristol generated the Rheumatoid Arthritis Patient Priorities for 
Pharmacological Interventions (RAPP-PI) core set to complement the existing professional 
core sets.(31)  This patient-driven study also identified independence as one of eight priority 
outcomes of pharmacological interventions in RA. In a Swedish qualitative study evaluating the 
patient perspective on benefits of RA treatment, independence was identified as a theme covering 
domains as management of daily activities, care for oneself and for one’s family, being able to work 
and enjoy leisure time.(32)  
In contrast, in the context of our remission work, independence emerged as a separate domain, 
grouped in the theme ‘decreased impact of RA’. When reviewing our qualitative work, the domain 
independence seems mainly related to physical functioning, i.e. ‘the ability to do things you have to 
do and not have to ask others to do things for you’. However, influence of other domains and factors 
like ability to work, performing one’s family role and comorbidities is highly likely and warrants 
further study. Similar overlap might exist between other domains while this could have been 
avoided by grouping of domains into larger themes.Indeed, if we would have grouped the domains 
socialize, family role, work and leisure into one domain ‘participation’, the ratings for this grouped 
domain would have exceeded that of independence in 2 out of 6 sites. However, we have chosen to 
present all 26 domains in our survey, using patient quotes from focus groups, so that patients could 
optimally relate to the domains. In the case of independence, this domain was chosen more often as 
a top 3 domain than related domains such as physical functioning, mobility, work or activities of 
daily living. However, these related domains scored high in the rating of essential domains, with 
mobility ranked second, physical function third, independence fourth and fatigue fifth. As our 
objective was to identify the three most important domains for RA patients to define a state of 
remission, we have chosen to rely on the report of top 3 domains, knowing that the ranking of 
essential domains pointed in a highly similar direction and that independence covers aspects of 
function/mobility. 
 
Some differences exist between different patient groups when stratified for age, gender, disease 
duration and the presence of comorbidities and damage; for example performing one’s family role 
was more important to younger patients compared to older patients. These differences were already 
predicted by patients during the qualitative phase and are confirmed by this survey study.  
In addition, some differences exist in the procedure of filling out the survey; we sent out two 
versions of the survey with a different (random) order of the domains, to reduce any order effect on 
decision-making. Although there was a difference in frequencies of domains reported in the top 3 
between patients that completed version 1 versus patients that completed version 2 of the survey, 
the three most often reported domains were still pain, fatigue and independence. It seemed that the 
higher the domain was listed in the survey, the more likely that patients would include the domain 
in their top 3, even though the top three was a separate section at the end of the survey. However, 
as the top 3 remained unchanged across the different versions, this order effect had no influence on 
the patients’ choice for the three most important domains. 
It can be questioned whether other domains besides the 26 identified from focus groups in Bristol, 
Amsterdam and Vienna would have emerged when groups were organised in Paris, Copenhagen and 
the US; the survey allowed patients to add additional domains. Seven patients used this 
opportunity, but this did not result in new domains, suggesting that the survey was comprehensive. 
Yet, this does not indicate generalisability of our results to countries beside those studied here. 
 
The majority of patients indicated they needed their symptoms to be ‘gone’ instead of ‘less’ or 
‘almost absent’ in order to reflect remission. Yet, patients that indicated themselves as currently in 
remission had a mean patient global assessment of 1.5. It remains a point of discussion how this 
relates to the ACR/EULAR remission definition, which requires that the patient global assessment of 
disease activity can be no greater than 1. Interpreting these data, one could argue that a score of 
less than 2 on a visual analogue scale from 0 to 10 equals ‘gone’ from a patient perspective. 
Alternatively, to adhere to the rule of 1, one could allow rounding to one for scores that go up to 
1.5.   Interesting is the contrast between patients’ rating of fatigue as a top 3 priority, yet needing it 
to be less (23%), almost gone (40%) or gone (37%) to reflect remission. This is different for the 
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other 4 important domains, in which the majority feels a certain domain needs to be gone, rather 
than almost gone or less. Perhaps fatigue is a domain that seriously impacts the lives of people with 
RA, but is somehow more manageable or acceptable than for example pain.  
 
Strengths of this study include the geographical spread of the patient sample as well as the dual 
analysis of domains, either within the top 3 of importance or rated most frequently as essential. The 
robustness of the results across countries and response modes enhances the reliability of the 
results. 
A weakness of this study is that the response rate wasn’t registered at every site, which might 
indicate that a selection of highly motivated patients was studied. When looking at the demographic 
characteristics, a heterogeneous pattern is observed, with a wide range in patients age, disease 
duration and remission experience. The size of our study population does not allow for extensive 
subgroup analysis. Yet the uniformity in a choice for a top three of patient important domains 
strengthens the importance of these three domains and suggests that these are  - to a certain level 
- independent of other patient characteristics.  
Another weakness of this study is the absence of extensive clinical data collection, which prohibited 
us from linking our results with other frequently used disease activity measures like the Clinical and 
Simplified Disease Activity Indices (except in a few patients). However, this work served primarily to 
identify the common top 3 of patient domains that need to be studied further in comparison with 
clinical measures.  
With this in mind, a validation study has been initiated, studying measurement instruments for the 
three most important domains of patient perceived remission identified in this study in relation to 
clinical outcome. It is anticipated that the results of the validation study will inform whether any of 
these three domains add important information to the ACR/EULAR remission criteria. 
  
In summary, this survey study identified the three most important domains of patient perceived 
remission, based on preceding qualitative research on the patient perspective on remission in RA. 
Follow up research has been initiated to identify valid measurement instruments for these domains 
and quantify the contribution to the ACR/EULAR remission criteria. 
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Table 4: Percentage of patients that rate a domain as essential to be reduced or absent / improved to define remission 
 Total Age Gender Disease duration Comorbidities Damage Place of filling out Version 
  ≤50 >50 male female ≤2yr >2 yr no yes no yes clinic home 1 2 
N 274 83 190 70 204 27 244 131 143 160 113 97 177 216 58 
Pain 60 71 56 55 62 57 61 62 59 59 62 56 62 62 54 
Fatigue 41 49 38 33 44 37 42 37 45 43 38 37 44 41 42 
Physical  funcion 51 58 48 49 52 59 51 53 50 52 51 52 51 52 47 
Independence 47 55 43 43 49 44 48 45 50 49 45 41 51 48 44 
Mobility 52 60 48 43 55 44 53 53 51 57 46 55 51 55 42 
Swelling 38 48 34 30 41 41 39 39 38 41 35 37 39 38 40 
Morning stiffness 24 29 22 20 25 0 15 24 24 21 28 22 25 26 18 
Stiffness 30 36 27 27 31 15 31 31 30 28 33 30 30 31 28 
Variability 23 26 21 20 23 15 23 21 24 23 23 21 23 23 19 
Unpredictability 25 30 21 17 27 37 24 24 25 27 21 21 27 26 19 
Flare 39 51 33 27 42 37 38 41 37 42 34 43 36 41 28 
Dmard usage 31 30 32 29 32 26 31 29 33 33 30 38 27 34 20 
Painkiller usage 26 31 24 21 28 26 26 27 25 26 27 29 24 28 19 
Mood 21 21 21 9 25 30 20 17 24 23 18 18 22 20 23 
Socialize 30 34 29 29 31 50 29 27 33 36 23 25 33 30 31 
Strength 27 29 26 26 28 44 53 28 27 28 27 24 29 30 16 
Grip 34 35 34 33 35 33 27 38 31 35 34 31 36 33 39 
Fine motor skills 36 43 33 31 38 48 35 37 35 36 36 31 39 36 35 
Activities of daily living 39 46 35 31 41 48 38 42 35 42 34 41 37 43 23 
Family role 37 54 30 29 40 33 37 41 33 45 26 33 39 37 36 
Work 33 51 25 30 34 27 33 33 32 41 22 33 33 35 25 
Doing leisure time activities 27 36 23 27 27 30 27 30 25 33 20 25 29 30 18 
Feeling as normal as other 
people around you 
26 35 22 19 29 33 26 25 27 30 21 22 29 30 11 
Being treated as normal as 
others by people around you 
28 36 24 19 31 33 28 29 27 30 25 22 31 30 20 
Mental power 40 46 37 29 44 48 39 41 39 44 35 36 42 41 35 
